May 31, 2024
Product: Drugs Recipient: Recipient Name Pascal Soriot Recipient Title Executive Director and Chief Executive Officer AstraZeneca Pharmaceuticals LP 1800 Concord PikeWilmington, DE 19850United States Issuing Office: […]
May 31, 2024
FDA’s Bad Ad Program is an outreach program designed to help healthcare providers recognize potentially false or misleading prescription drug promotion. The program’s goal is to […]
May 31, 2024
Office of Prescription Drug Promotion Content current as of: 05/31/2024 Regulated Product(s)
May 31, 2024
The Committee for Medicinal Products for Human Use (CHMP) has recommended dropping a previous ban on donations of blood or plasma for fractionation from individuals who […]
May 31, 2024
In its May 2024 meeting, the European Medicines Agency (EMA) gave the go-ahead for Durveqtix to treat severe and moderately severe hemophilia B in adults who […]
May 31, 2024
The European Medicines Agency (EMA) has recommended granting a marketing authorization in the European Union for Ixchiq (Valneva Austria), the first vaccine for EU countries intended […]
May 31, 2024
FDA’s Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) initiated the Support for clinical Trials Advancing Rare disease Therapeutics […]
May 31, 2024
On July 9, 2012, the President signed into law the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012. This new law includes the […]
May 31, 2024
TOPLINE: Fluoroquinolones don’t increase the risk for severe hypoglycemia compared with amoxicillin in older patients with diabetes treated with second-generation sulfonylureas, but caution is warranted in […]